Optimising ovarian tumour management: - Optimising ovarian tumour management: a multicentre study of the short and long term effects of the surgical versus conservative management of ovarian masses
From 01-01-2012 to 31-12-2015
Description
The long term behaviour of benign-looking ovarian masses that do not undergo surgery is unknown. Such masses may undergo malignant transformation, rupture or torsion. Furthermore, they may undergo changes in volume and/or morphology that may or may not predict any of these behaviours. Due to lack of research efforts, there are no evidence-based guidelines on the optimal management of the majority of ovarian tumours. It is therefore not surprising that clinical practice is highly variable regarding the decision for surgery and follow-up schedule.
Developing new insights into the natural history of benign looking conservatively managed ovarian masses will impact on patient management by avoiding surgery or surveillance for some and detecting cancer earlier or even preventing it for others. This international multicentre study aims to develop the optimal evidence-based algorithm for the management of all ovarian tumours. At least 3000 patients with an ovarian mass will undergo an ultrasound examination and if no operation is needed they will be followed up for at least 5 years. At each visit the investigator assesses the tumour and decides whether surgery is necessary. Survival and logistic regression analysis will be used to develop decision aids to assist clinicians in making optimal management decisions.
Team
- Dirk Timmerman, Co-promoter (External)
- Ben Van Calster, Promoter
Financing
Funding: FWO - Research Foundation - Flanders
Program/Grant Type: FWO Research Grant - FWO Research Grant
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.